AssetMark Inc’s Cellectis CLLS Stock Holding History

AssetMark Inc’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,721	Closed	-$5.35K	–	1751
2023 Q2	$5.35K	Buy	2,721 +810	+42%	+$1.55K	﹤0.01%	1345
2023 Q1	$3.69K	Buy	1,911 +391	+26%	+$979	﹤0.01%	1350
2022 Q4	$3.19K	Buy	1,520 +380	+33%	+$861	﹤0.01%	1397
2022 Q3	$3K	Buy	1,140 +275	+32%	+$833	﹤0.01%	1348
2022 Q2	$2K	Buy	865 +505	+140%	+$1.78K	﹤0.01%	1361
2022 Q1	$2K	Buy	+360	New	+$1.98K	﹤0.01%	1401

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AssetMark Inc's CLLS Position: Q3 2023 in Review

AssetMark Inc sold out of Cellectis (CLLS) in Q3 2023, closing a stake of 2,721 shares — an estimated $5.35K sold.

AssetMark Inc first reported a position in CLLS in Q1 2022 and held it in 6 quarters. The position peaked at $5.35K in Q2 2023. 31 funds tracked by Wall St. Rank hold CLLS as of Q3 2023.

AssetMark Inc reported no remaining Cellectis position as of Q3 2023 after selling out during the quarter.
AssetMark Inc sold 2,721 Cellectis shares in Q3 2023, an estimated $5.35K.
AssetMark Inc first reported a position in Cellectis in Q1 2022 and held it in 6 quarters.
AssetMark Inc's Cellectis position peaked at $5.35K in Q2 2023.
31 funds tracked by Wall St. Rank held Cellectis as of Q3 2023.

Based on AssetMark Inc's 13F filing for Q3 2023, filed 27 Oct 2023.